A long-lasting formulation of an antiviral drug greatly reduced people’s risk of a symptomatic flu infection in a trial, and ...

Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

Influenza significantly impacted adults aged 50 to 64 years and younger adults with chronic conditions, but risk can be reduced with RIV.

Moderna's flu vaccine candidate, mRNA-1010, shows 26.6% efficacy in a Phase 3 trial for adults 50+. Read more here.

New research shows cumin extract can prevent flu virus infection in lab cells. It works by stopping the virus from attaching ...